← Back to patent-cliff list
Alprostadil Liposome for Injection(CSPC Zhongqi Pharma)
Tier C — Watch / tradeAlprostadil Liposome for Injection(CSPC Zhongqi Pharma)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Prostaglandin
Indications (approved)：闭塞性动脉硬化, 急性肾损伤, 造影剂肾病, Arterial occlusive disease
Regional status
US
-
EU
-
China
Phase II
2019-09-30
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Alprostadil Liposome for Injection(CSPC Zhongqi Pharma)?
Approved indications include: 闭塞性动脉硬化, 急性肾损伤, 造影剂肾病, Arterial occlusive disease.
When does the Alprostadil Liposome for Injection(CSPC Zhongqi Pharma) patent expire?
No public expiry year is available for Alprostadil Liposome for Injection(CSPC Zhongqi Pharma) yet; this page updates once verified.
How do I get a quote for Alprostadil Liposome for Injection(CSPC Zhongqi Pharma) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-07